The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How will the results of the phase III ASCEND trial change treatment practice of R/R CLL?

Jun 24, 2019

During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Paolo Ghia from University Vita-Salute San Raffaele, Milan, IT, about how the results of the phase III ASCEND trial might change treatment practice of relapsed/refractory chronic lymphocytic leukemia (CLL).

Paolo Ghia discusses how the multicenter, international study compared a classic chemotherapy treatment with a chemotherapy-free treatment, and with a novel BTK inhibitor. He mentions how, for the first time, two chemotherapy-free treatments were compared.

How will the results of the phase III ASCEND trial change treatment practice of R/R CLL?